Bristol-Myers Squibb (BMY) and AstraZeneca (AZN) win the battle for Amylin (AMLN), agreeing to...

|About: Bristol-Myers Squibb Com... (BMY)|By:, SA News Editor

Bristol-Myers Squibb (BMY) and AstraZeneca (AZN) win the battle for Amylin (AMLN), agreeing to buy the diabetes drug maker for $31/share (10% premium to Friday's close). The total size of the deal is $7B, and includes about $3.4B from AZN, which will expand its diabetes collaboration with Bristol. (PR)